1. SIRT4 loss reprograms intestinal nucleotide metabolism to support proliferation following perturbation of homeostasis.
- Author
-
Tucker SA, Hu SH, Vyas S, Park A, Joshi S, Inal A, Lam T, Tan E, Haigis KM, and Haigis MC
- Subjects
- Animals, Humans, Mice, Glutamine metabolism, Homeostasis, Intestinal Mucosa metabolism, Mice, Inbred C57BL, Mitochondrial Proteins, Nucleotides metabolism, Organoids metabolism, Cell Proliferation, Intestinal Neoplasms metabolism, Intestinal Neoplasms pathology, Intestinal Neoplasms genetics, Intestines metabolism, Intestines pathology, Sirtuins metabolism
- Abstract
The intestine is a highly metabolic tissue, but the metabolic programs that influence intestinal crypt proliferation, differentiation, and regeneration are still emerging. Here, we investigate how mitochondrial sirtuin 4 (SIRT4) affects intestinal homeostasis. Intestinal SIRT4 loss promotes cell proliferation in the intestine following ionizing radiation (IR). SIRT4 functions as a tumor suppressor in a mouse model of intestinal cancer, and SIRT4 loss drives dysregulated glutamine and nucleotide metabolism in intestinal adenomas. Intestinal organoids lacking SIRT4 display increased proliferation after IR stress, along with increased glutamine uptake and a shift toward de novo nucleotide biosynthesis over salvage pathways. Inhibition of de novo nucleotide biosynthesis diminishes the growth advantage of SIRT4-deficient organoids after IR stress. This work establishes SIRT4 as a modulator of intestinal metabolism and homeostasis in the setting of DNA-damaging stress., Competing Interests: Declaration of interests M.C.H. received research funding from Agilent Technologies and Roche Pharmaceuticals. M.C.H. serves on the scientific advisory boards of Alixia, Minovia, and MitoQ and is on the editorial boards of Cell Metabolism and Molecular Cell. S.V. served as a Cell Reports editor between 2018 and 2021 and is currently the lead editor for Cell Press Multi-Journal Submission. She carried out the work reported in this paper before joining Cell Press. She was not given access to information related to the peer review of this paper, nor did she participate in the decision-making process. K.M.H. received research funding from Novartis and TUO Therapeutics., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF